Dogwood Therapeutics (DWTX) Company Report

Dogwood Therapeutics, Inc. (DWTX) entered into an Equity Distribution Agreement on November 28, 2025, establishing an "at-the-market" (ATM) offering program.
Under this program, the company can issue and sell shares of its common stock with an aggregate offering price of up to $8,558,712.
Northland Securities, Inc. will act as the sales agent for the program, receiving a commission of 3.0% of the gross offering proceeds from shares sold.
The shares to be sold represent 21.38% of the value of the company's outstanding common stock held by non-affiliates.

Nov 28, 2025, 7:15 PM

8-K

Dogwood Therapeutics Stockholders Approve Amended Equity Plan and Preferred Stock Conversion

DWTX

Executive Compensation

M&A

Proxy Vote Outcomes

Dogwood Therapeutics, Inc. stockholders approved the Second Amended and Restated Equity Incentive Plan on November 21, 2025.
This plan increases the number of shares of common stock reserved for issuance by 2,781,665 shares, bringing the total to 2,972,787 shares available for grants. This total reflects a 25-for-1 reverse stock split effective October 9, 2024.
Stockholders also approved the potential issuance of common stock upon conversion of Series A, A-1, and A-2 Non-Voting Convertible Preferred Stock.
The approval of the Series A conversion finalized the business combination with Sealbond Limited.

Nov 21, 2025, 6:01 PM

8-K

Dogwood Therapeutics Stockholders Approve Key Proposals at Special Meeting

DWTX

Convertible Preferred Issuance

Proxy Vote Outcomes

Executive Compensation

Dogwood Therapeutics held a special meeting of stockholders on November 21, 2025, where five proposals were presented for approval.
Stockholders approved the issuance of common stock upon conversion of Series A, A1, and A2 non-voting convertible preferred stock, in compliance with NASDAQ Listing Rule 5635.
The Dogwood Therapeutics Second Amended and Restated 2020 Equity Incentive Plan was also approved.
The record date for voting was October 14, 2025, with 2,293,162 shares of common stock outstanding and a quorum present.

Nov 21, 2025, 3:00 PM

Transcript

Dogwood Therapeutics Stockholders Approve Key Proposals at Special Meeting

DWTX

Proxy Vote Outcomes

Convertible Preferred Issuance

Executive Compensation

Dogwood Therapeutics held a special meeting of stockholders on November 21, 2025, where all five proposals presented were approved.
Stockholders approved the issuance of common stock upon conversion of Series A, Series A1, and Series A2 non-voting convertible preferred stock to comply with NASDAQ Listing Rule 5635.
The Dogwood Therapeutics Second Amended and Restated 2020 Equity Incentive Plan was also approved.
The record date for voting was October 14, 2025, with 2,293,162 shares of common stock issued and outstanding.

Nov 21, 2025, 3:00 PM

Transcript

Dogwood Therapeutics Stockholders Approve Key Proposals

DWTX

Proxy Vote Outcomes

Convertible Preferred Issuance

Executive Compensation

Dogwood Therapeutics held a special meeting on November 21, 2025, led by CEO and Chairman Greg Duncan and CFO and Secretary Angela Walsh.
Stockholders voted on five proposals, including the approval of common stock issuance upon conversion of Series A, A1, and A2 non-voting convertible preferred stock.
The proposals also included the approval of the Dogwood Therapeutics Second Amended and Restated 2020 Equity Incentive Plan.
All five proposals were approved by the stockholders.

Nov 21, 2025, 3:00 PM

Transcript

Dogwood Therapeutics Reports Q3 2025 Financial Results and Operational Updates

DWTX

Earnings

New Projects/Investments

Dogwood Therapeutics, Inc. (DWTX) reported a net loss attributable to common stockholders of $15.7 million, or $8.20 basic and diluted net loss per share, for the third quarter ended September 30, 2025, compared to a net loss of $2.3 million, or $2.05 per share, for the third quarter of 2024.
Research and development expenses increased to $14.5 million for Q3 2025, up from $0.5 million in Q3 2024, primarily due to $12.0 million associated with the licensing agreement of SP16.
The company secured an exclusive worldwide, royalty-free license to develop and commercialize SP16 as a synergistic and complementary pipeline treatment for cancer-related pain through an all-stock transaction.
Enrollment for the Halneuron® Phase 2b trial reached 100 patients, with an interim analysis remaining on track for Q4 2025 release.
Cash on hand of $10.1 million as of September 30, 2025, provides an operational runway through the first quarter of 2026.

Nov 6, 2025, 2:15 PM

8-K

Dogwood Therapeutics, Inc. Provides Update on Neuropathy Treatments and Milestones

DWTX

New Projects/Investments

Guidance Update

Dogwood Therapeutics, Inc. (DWTX) is advancing two primary candidates for cancer-related neuropathy: Halneuron® (TTX), a Nav1.7 channel blocker, and SP16, an LRP1-agonist.
Halneuron® is currently in an ongoing Phase 2b study for Chemotherapy-Induced Neuropathic Pain (CINP), with over 80 patients randomized and 60 completed treatment as of Q3 2025. An interim data readout for this study is projected for Q4 2025.
SP16 is in early clinical stage development for Chemotherapy-Induced Peripheral Neuropathy (CIPN), with a Phase 1b safety study planned for patient enrollment in 1H 2026 following an IND filing in Q4 2025. This program is fully funded by NCI through its next clinical milestone.
Upon conversion of existing Preferred Stock, there will be approximately 30 million shares of common stock on a fully diluted basis, with CK Life Sciences Int’l. and Serpin Pharma expected to own approximately 90% of DWTX stock combined.

Oct 9, 2025, 8:15 PM

8-K

Dogwood Therapeutics Provides Update on Halneuron® and SP16 Clinical Programs

DWTX

New Projects/Investments

Dogwood Therapeutics is progressing its Halneuron® Na 1.7 program for Chemotherapy-Induced Neuropathic Pain (CINP), with 80 patients randomized in the ongoing Phase 2b study out of a target enrollment of 200 patients. An interim data readout for this study is projected for Q4 2025.
The company has secured a royalty-free, global license for Serpin Pharma's IV formulation of SP16, a clinical-stage candidate for neuropathy and nerve damage. The Phase 1b trial for SP16 is fully funded by the National Cancer Institute (NCI), with an IND filing planned for Q4 2025 and patient enrollment starting in 1H 2026.
This new license expands Dogwood's pipeline, with SP16 offering potential for nerve repair and prevention that could synergistically complement Halneuron® in treating CINP.
Key upcoming milestones for Q4 2025 include filing new synthetic Halneuron® IP, recruiting 100 patients in the Halneuron® Phase 2b study, the Halneuron® Phase 2b interim data readout, and filing the SP16 IND.

Sep 29, 2025, 12:30 PM

Presentation

Dogwood Therapeutics Licenses SP Sixteen and Provides Clinical Updates

DWTX

M&A

New Projects/Investments

Guidance Update

Dogwood Therapeutics (DWTX) has secured a global license to develop and commercialize SP sixteen, a first-in-class LRP one agonist, as a complementary treatment for chemotherapy-induced peripheral neuropathy (CIPN).
The SP sixteen acquisition is an all-stock transaction with no royalty obligations or future development milestones, and its Phase 1b clinical research is fully funded by the National Cancer Institute (NCI).
Dogwood plans to file an IND for SP sixteen in Q4 2025 and expects to commence patient dosing in H1 2026.
The company also provided an update on its lead compound, Halneuron, reporting 82 patients enrolled in its Phase 2b study for CIPN, with an interim analysis anticipated by December (Q4 2025).

Sep 29, 2025, 12:30 PM

Transcript

Dogwood Therapeutics Licenses SP16 and Provides L-Neuron Study Update

DWTX

M&A

New Projects/Investments

Dogwood Therapeutics has acquired a global license to develop and commercialize SP16, a first-in-class LRP1 agonist, intended to complement its lead compound, L-Neuron, for chemotherapy-induced peripheral neuropathy (CINP).
The licensing deal for SP16 is an all-stock transaction with no royalties or future development milestones, resulting in Serpent Pharma owning approximately 7.31% of Dogwood Therapeutics on a fully diluted basis.
The forthcoming Phase 1b clinical trial for SP16 is fully funded by the National Cancer Institute (NCI) and is expected to begin enrolling patients in the first half of 2026, with safety and tolerability as primary endpoints.
Dogwood Therapeutics provided an update on its ongoing L-Neuron Phase 2b study for CINP, which has enrolled 82 patients out of a target of 200. An interim analysis is planned for Q4 2025, and final data is expected in mid-2026.